

- **Name:** Lucksamon Thamlikitkul, MD, PhD
 - **Current Position & Affiliation:** Assistant Professor
Division of Medical Oncology
Department of Medicine
Faculty of Medicine Siriraj Hospital
Mahidol University
 - **Country:** Thailand
-

• **Educational Background:**

- Doctor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
- Thai Board of Medicine and Medical Oncology
- Master of Science (Cancer), University College London
- Doctor of Philosophy, Imperial College London

• **Professional Experience:**

- Assistant Professor, Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University (2024 – now)
- Secretary and Board Member, Siriraj Cancer Center, Faculty of Medicine Siriraj Hospital, Mahidol University (2023 – now)
- Board Member, Siriraj Metabolomics and Phenomics Center, Faculty of Medicine Siriraj Hospital, Mahidol University (2023 – now)

• **Professional Organizations:**

- Active Member of TSCO, IASLC, ESMO, ASCO, AACR
- ESMO Leadership Generation Programme Asia Alumni (2022)
- ASCO International Development and Education Awardee (2017)

• **Main Scientific Publications:**

1. Jantarat A, Thamlikitkul L, Thephamongkhon K et al. Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial. JCO Glob Oncol. 2025.
2. Thamlikitkul L, Parinyanitikul N, Sriuranpong V. Genomic medicine and cancer clinical trial in Thailand. Cancer Biol Med. 2023.
3. Chrysostomou S, Roy R, Prisci F, Thamlikitkul L, Chapman K. et al. Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Sci Transl Med. 2021.

• **Active Research Projects (Principal Investigator):**

- Minimal residual disease (MRD) detection in resected non-small cell lung cancer patients using long-read sequencing technology and comprehensive multi-omics

- study for molecular characterization of non-small cell lung cancer in Thai patients
- Plasma metabolomics in EGFR-mutated non-small cell lung cancer
 - Economic analysis of immunotherapy for non-oncogene addicted advanced non-small cell lung cancer
 - Clinical effectiveness, cost-utility, and budget impact analyses of osimertinib as a first-line treatment for EGFR-mutated advanced-stage non-small cell lung cancer in Thailand
 - Comparison between EGFR real-time polymerase chain reaction (PCR) and gene panel PCR with targeted next-generation sequencing (NGS) for detection of oncogenic driver alteration in non-small cell lung cancer patients
 - Randomized controlled trial of standard care with or without early palliative care provided by palliative care specialist in advanced non-small cell lung cancer patients